Search research articles
Contact Us
Filters
Showing results (531-540 of 603) with videos related to
Page
of 61
Sort By:
Clinical Spine Surgery
|
April 21, 2025
Do Patients With High ASA Grades Benefit From CSM Surgery?: A Report From the Quality Outcomes Database
Vardhaan S Ambati, Arati Patel, Abraham Dada, et al.
The Lancet. Oncology
|
June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Biorxiv : the Preprint Server for Biology
|
November 1, 2024
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer
Ching-Fei Li, Li-Yuan Bai, Yongkun Wei, et al.
British Journal of Neurosurgery
|
February 23, 2016
Rapid improvements in pain and quality of life are sustained after surgery for spinal metastases in a large prospective cohort
David Choi, Zoe Fox, Todd Albert, et al.
Acta Neurochirurgica
|
January 19, 2020
How good are the outcomes of instrumented debulking operations for symptomatic spinal metastases and how long do they stand? A subgroup analysis in the global spine tumor study group database
Bart Depreitere, Federico Ricciardi, Mark Arts, et al.
Leukemia
|
April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R Furman, John C Byrd, Roger G Owen, et al.
Blood
|
April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Lihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
British Journal of Haematology
|
December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
Dai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
The Lancet. Oncology
|
December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
Nathan H Fowler, R Eric Davis, Seema Rawal, et al.
Blood Advances
|
December 3, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
Xiaoshan Zhang, Ran Zhang, Chenghui Ren, et al.
Page
of 61
Search research articles
Search
Showing results (531-540 of 603) with videos related to
Sort By:
Page
of 61
Clinical Spine Surgery
|
April 21, 2025
Do Patients With High ASA Grades Benefit From CSM Surgery?: A Report From the Quality Outcomes Database
Vardhaan S Ambati, Arati Patel, Abraham Dada, et al.
The Lancet. Oncology
|
June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Biorxiv : the Preprint Server for Biology
|
November 1, 2024
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer
Ching-Fei Li, Li-Yuan Bai, Yongkun Wei, et al.
British Journal of Neurosurgery
|
February 23, 2016
Rapid improvements in pain and quality of life are sustained after surgery for spinal metastases in a large prospective cohort
David Choi, Zoe Fox, Todd Albert, et al.
Acta Neurochirurgica
|
January 19, 2020
How good are the outcomes of instrumented debulking operations for symptomatic spinal metastases and how long do they stand? A subgroup analysis in the global spine tumor study group database
Bart Depreitere, Federico Ricciardi, Mark Arts, et al.
Leukemia
|
April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R Furman, John C Byrd, Roger G Owen, et al.
Blood
|
April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Lihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
British Journal of Haematology
|
December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
Dai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
The Lancet. Oncology
|
December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
Nathan H Fowler, R Eric Davis, Seema Rawal, et al.
Blood Advances
|
December 3, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
Xiaoshan Zhang, Ran Zhang, Chenghui Ren, et al.
Page
of 61